Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
Journal article published in 2020 by
Christian Winther Eskelund 
,
Simon Husby,
Francesco Favero ,
Tobias Wirenfeldt Klausen,
Francisco German Rodriguez-Gonzalez ,
Arne Kolstad,
Lone Bredo Pedersen,
Riikka Katariina Räty,
Christian H. Geisler,
Mats Jerkeman,
Joachim Weischenfeldt ,
Kirsten Grønbæk
,
Simon Husby,
Francesco Favero ,
Tobias Wirenfeldt Klausen,
Francisco German Rodriguez-Gonzalez ,
Arne Kolstad,
Lone Bredo Pedersen,
Riikka Katariina Räty,
Christian H. Geisler,
Mats Jerkeman,
Joachim Weischenfeldt ,
Kirsten Grønbæk
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Eskelund et al examined clonal hematopoiesis (CH) in a cohort of patients with mantle cell lymphoma (MCL) treated with first-line chemotherapy and autologous stem cell transplantation. In young, good-risk MCL patients, CH after first-line therapy arises almost entirely from preexisting clones, stabilizes after a period of expansion posttransplantation, and does not negatively impact survival.